Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418301 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL17975737 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL6399736 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL11438817 | 0.89 | USP2 (0.53) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL8946366 | 0.89 | USP2 (0.53) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL26358941 | 0.87 | USP2 (0.51) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL6402165 | 0.87 | USP2 (0.51) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL7152895 | 0.85 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL17326916 | 0.84 | PTPN1 (0.68) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL12154605 | 0.84 | PTPN1 (0.68) | USP2POLBMEN1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019074887-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-2367837-B1 | 1'-SUBSTITUTED RIBOSE 5'-POLYPHOSPHATE ANALOGS AND THEIR USE AS MODULATORS OF P2Y RECEPTOR ACTIVITY | MICRODOSE THERAPEUTX INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160129036-A1 | ADENOSINE ANALOGS AND THEIR USE | MICRODOSE THERAPEUTX INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9255121-B2 | Adenosine analogs and their use | MICRODOSE THERAPEUTX, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140038912-A1 | ADENOSINE ANALOGS AND THEIR USE | MICRODOSE THERAPEUTX, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569259-B2 | Adenosine analogs and their use | MICRODOSE THERAPEUTX, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2008060632-A2 | ADENOSINE ANALOGS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129036-A1 | ADENOSINE ANALOGS AND THEIR USE | P2RY2, P2RY1, P2RY11 | USP2 1379/4885POLB 842/4885MEN1 3793/4885 |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | USP2 4174/4885POLB 1585/4885MEN1 2427/4885 |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | USP2 4165/4885POLB 31/4885MEN1 1929/4885 |
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, NTPCR | USP2 3732/4885POLB 40/4885MEN1 2386/4885 |
| US-20140038912-A1 | ADENOSINE ANALOGS AND THEIR USE | P2RY2, P2RY1, P2RY11 | USP2 1539/4885POLB 632/4885MEN1 4117/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | USP2 4165/4885POLB 31/4885MEN1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.